Natural cytotoxicity triggering receptor 1 ligand (NKp46L)

NKp46 ligands (NKp46L) are a heterogeneous group of molecules expressed on the surface of tumor cells, virally infected cells, and stressed cells, such as fibroblast-like synoviocytes (FLS) in rheumatoid arthritis. These ligands are recognized by the NKp46 receptor (also known as NCR1 or CD335) on Natural Killer (NK) cells, serving as a critical "altered-self" signal that triggers NK cell activation, degranulation, and the release of pro-inflammatory cytokines like IFN-gamma (Source: Kruse et al., 2014, PubMed: 24711620). Known endogenous ligands include surface-exposed vimentin, calreticulin, heparan sulfate proteoglycans, and BAG6, as well as viral proteins like hemagglutinin (Source: Pazina et al., 2017, PubMed: 28611741). In oncology, these ligands facilitate the identification and elimination of malignant cells by the innate immune system. In the context of rheumatoid arthritis, RA-FLS have been shown to aberrantly express NKp46 ligands, which recruit and activate NK cells within the synovium, contributing to chronic inflammation and joint destruction (Source: Zhang et al., 2012, PubMed: 22496315). Therapeutic strategies targeting this axis primarily involve NK cell engagers (NKCEs), such as SAR443579, which are multi-specific antibodies designed to bridge the NKp46 receptor to specific tumor antigens, effectively bypassing or augmenting natural ligand-receptor interactions to promote targeted cell lysis (Source: Gauthier et al., 2019, PubMed: 31142854). Understanding the regulation of these ligands is essential for developing therapies that can either enhance tumor clearance or dampen pathological immune responses in inflammatory diseases.

Other names

NCR1 ligandNKp46-binding partnerNatural killer cell p46-related ligandNKp46-L

NK cell engagement and redirection of cytotoxicity via NKp46-mediated signaling; induction of antibody-dependent cell-mediated cytotoxicity (ADCC) mimicry; enhancement of NK cell-mediated lysis of ligand-positive cells.